|Other Names||Zinc finger and BTB domain-containing protein 16, Promyelocytic leukemia zinc finger protein, Zinc finger protein 145, Zinc finger protein PLZF, ZBTB16, PLZF, ZNF145|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6664b was selected from the C-term region of human PLZF. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Probable transcription factor. May play a role in myeloid maturation and in the development and/or maintenance of other differentiated tissues. Probable substrate-recognition component of an E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins.|
|Tissue Location||Within the hematopoietic system, PLZF is expressed in bone marrow, early myeloid cell lines and peripheral blood mononuclear cells. Also expressed in the ovary, and at lower levels, in the kidney and lung|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
PLZF is a member of the Krueppel C2H2-type zinc-finger protein family and a zinc finger transcription factor that contains nine Kruppel-type zinc finger domains at the carboxyl terminus. This protein is located in the nucleus, is involved in cell cycle progression, and interacts with a histone deacetylase. Specific instances of aberrant gene rearrangement at this locus have been associated with acute promyelocytic leukemia (APL).
Shi,J., Int. J. Cancer 125 (7), 1558-1565 (2009)Doulatov,S., Genes Dev. 23 (17), 2076-2087 (2009)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.